scholarly journals Growth Inhibition of Human Breast and Prostate Cancer Cells by Cinnamic Acid Derivatives and Their Mechanism of Action

2019 ◽  
Vol 42 (7) ◽  
pp. 1134-1139 ◽  
Author(s):  
Masahiko Imai ◽  
Hiromasa Yokoe ◽  
Masayoshi Tsubuki ◽  
Noriko Takahashi
Keyword(s):  
Prostate Cancer ◽  
Growth Inhibition ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Cinnamic Acid ◽  
Human Breast ◽  
Prostate Cancer Cells ◽  
Cinnamic Acid Derivatives ◽  
Breast And Prostate Cancer

Proliferative effect of whey from cows’ milk varying in phyto-oestrogens in human breast and prostate cancer cells

2012 ◽  
Vol 79 (2) ◽  
pp. 143-149 ◽  
Author(s):  
Tina S. Nielsen ◽  
Annika Höjer ◽  
Anne-Maj Gustavsson ◽  
Jens Hansen-Møller ◽  
Stig Purup
Keyword(s):  
Prostate Cancer ◽  
Cell Proliferation ◽  
Cancer Cells ◽  
Dietary Treatment ◽  
Human Breast ◽  
Prostate Cancer Cells ◽  
Proliferative Effect ◽  
Significant Difference ◽  
Breast And Prostate Cancer ◽  
Mcf 7

Intake of dietary phyto-oestrogens has received a great deal of attention owing to their potential influence on hormone-sensitive cancers such as breast and prostate cancer. Cows’ milk contains phyto-oestrogens and the content varies according to the composition of the feed and the type and amount of legumes used. In this study we evaluated the proliferative effect of milk (whey) with different phyto-oestrogen content in human breast (MCF-7) and prostate cancer cells (PC-3). Milk was obtained from cows fed either a birdsfoot trefoil-timothy silage based ration (B1) or two different red clover silage based diets (R1 and R2) resulting in total phyto-oestrogen contents of 403, 1659 and 1434 ng/ml for the B1, R1 and R2 diets, respectively. Whey was produced from the milk and added to cell culture medium in concentrations up to 10% for MCF-7 cells and 5% for PC-3 cells. Cell proliferation was measured fluorometrically after 7 d for MCF-7 cells and 5 d for PC-3 cells. There was no significant difference in the proliferative effect of whey from the different dietary treatments at any of the whey concentrations tested. An anti-proliferative effect (P<0·01) of 5 and 10% whey was seen when tested in the presence of 10 pmoestradiol in the medium. This effect was independent of dietary treatment of cows. Whey induced a significant (P<0·01) proliferative response in PC-3 cells independent of dietary treatment. Purified equol in concentrations similar to equol concentrations in milk decreased PC-3 cell proliferation, and therefore the stimulatory effect of whey in PC-3 cells is believed to be mediated by other bioactives than equol. In conclusion, our results suggest that using whey in these proliferation assays, it was not possible to discriminate between milk with high or low levels of phyto-oestrogens.

MnSOD Up-Regulates Maspin Tumor Suppressor Gene Expression in Human Breast and Prostate Cancer Cells

2003 ◽  
Vol 5 (5) ◽  
pp. 677-688 ◽  
Author(s):  
Hong Duan ◽  
Hannah J. Zhang ◽  
Ji-Qin Yang ◽  
Larry W. Oberley ◽  
Bernard W. Futscher ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Tumor Suppressor ◽  
Cancer Cells ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Human Breast ◽  
Prostate Cancer Cells ◽  
Breast And Prostate Cancer

scholarly journals Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro

2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Nik Soriani Yaacob ◽  
Nurraihana Hamzah ◽  
Nik Nursyazni Nik Mohamed Kamal ◽  
Siti Amalina Zainal Abidin ◽  
Choon Sheen Lai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Human Breast ◽  
Prostate Cancer Cells ◽  
Strobilanthes Crispus ◽  
Breast And Prostate Cancer

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

2004 ◽  
Vol 11 (4) ◽  
pp. 793-814 ◽  
Author(s):  
H E Jones ◽  
L Goddard ◽  
J M W Gee ◽  
S Hiscox ◽  
M Rubini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Growth Factor ◽  
Growth Inhibition ◽  
Cancer Cells ◽  
Cell Line ◽  
Acquired Resistance ◽  
Continuous Exposure ◽  
Prostate Cancer Cells ◽  
Breast And Prostate Cancer

De novo and acquired resistance to the anti-tumour drug gefitinib (ZD1839; Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been reported. We have determined whether signalling through the IGF-I receptor (IGF-1R) pathway plays a role in the gefitinib-acquired resistance phenotype. Continuous exposure of EGFR-positive MCF-7-derived tamoxifen resistant breast cancer cells (TAM-R) to 1 μM gefitinib resulted in a sustained growth inhibition (90%) for 4 months before the surviving cells resumed proliferation. A stable gefitinib-resistant subline (TAM/TKI-R) was established after a further 2 months and this showed no detectable basal phosphorylated EGFR activity. Compared with the parental TAM-R cells, the TAM/ TKI-R cells demonstrated (a) elevated levels of activated IGF-1R, AKT and protein kinase C (PKC)δ, (b) an increased sensitivity to growth inhibition by the IGF-1R TKI AG1024 and (c) an increased migratory capacity that was reduced by AG1024 treatment. Similarly, the EGFR-positive androgen-independent human prostate cancer cell line DU145 was also continuously challenged with 1 μM gefitinib and, although substantial growth inhibition (60%) was seen initially, a gefitinib-resistant variant (DU145/TKI-R) developed after 3 months. Like their breast cancer counterparts, the DU145/TKI-R cells showed increases in the levels of components of the IGF-1R signalling pathway and an elevated sensitivity to growth inhibition by AG1024 compared with the parent DU145 cell line. Additionally, DU145/TKI-R cell migration was also decreased by this inhibitor. We have therefore concluded that in breast and prostate cancer cells acquired resistance to gefitinib is associated with increased signalling via the IGF-1R pathway, which also plays a role in the invasive capacity of the gefitinib-resistant phenotype.

Sign in / Sign up

Export Citation Format

Share Document